As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

As the year comes to a close, it's time to look back at the numerous innovations across the diabetes technology industry in ...

MiniMed is pitching the breadth of its portfolio as an advantage over more focused rivals such as Dexcom and Insulet.

Earlier on November 25, Evercore ISI initiated coverage of DexCom with an In Line rating and $68 price target. While ...

The model, 34, and the comedian, 37, who are parents to daughter Elsie, two, became engaged when he popped the question in ...

GlucoModicum today unveiled Sofio, which it labels the world's first needle-free glucose monitor based on magneto-hydrodynamics (MHD).

In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings. The recall affects approximately 3 million sensors and was caused by an ...

Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, aimed at adults who are not using insulin but still want detailed glucose ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...